StudyFinder
A double-blind, randomized, placebo-controlled study to assess the safety and efficacy of nebulized PC945 when added to systemic antifungal therapy for the treatment of refractory invasive pulmonary aspergillosis
Recruiting
The purpose of this study is to learn about the safety and efficacy of PC945 when given in combination with the antifungal therapy that is normally given for this condition, also known as the standard of care (SoC). This study will also assess how PC945 is processed in the body (e.g., distributed, transformed, and removed) by measuring the levels of PC945 in your blood and lungs; this is called pharmacokinetics (PK).
Male or Female
18 years and over
Inclusion Criteria:
• diagnosis of invasive pulmonary aspergillosis that hasn't responded to treatment
Exclusion Criteria:
• surgical or medical condition that makes participation difficult or potentially unsafe
• require care in an intensive care unit
Drug: PC945, Drug: Placebo
Breathing, Lung & Sleep Health, Infectious Diseases
Clinics and Surgery Center (CSC), antifungal therapy, aspergillosis, fungal infection, lung infection, pulmonary aspergillosis
Lindsey Raymond - raymo139@umn.edu
Jo-Anne Young, MD
STUDY00017568
See this study on ClinicalTrials.gov